Want to see AU:OSL full AI Analyst Report?
OSL Stock Chart & Stats
AU$0.97
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.97
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.37 - AU$2.08
Previous CloseN/A
Volume350.23K
Average Volume (3M)24.03K
Market Cap
AU$38.92M
Enterprise ValueAU$15.20
Total Cash (Recent Filing)AU$2.85M
Total Debt (Recent Filing)AU$42.47K
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding30,889,430
10 Day Avg. Volume8,764
30 Day Avg. Volume24,029
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.23
Price to Sales (P/S)11.20
P/FCF Ratio-1.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$4.60M
Bulls Say, Bears Say
Bulls Say
Differentiated Core Product (targeted Brachytherapy)OncoSil’s device is a specialized, procedure‑based therapy for locally advanced pancreatic cancer. That clinical differentiation creates durable barriers to entry (training, procedure integration, clinical data) and supports longer‑term adoption, reimbursement discussions and pricing power versus commodity devices.
Sustained Revenue GrowthConsistent double‑digit revenue growth indicates commercial traction and expanding adoption of the core product. Sustained top‑line momentum improves the company’s ability to invest in trials, market development and scale operations, reducing execution risk over the next several months.
Very Low Financial LeverageMinimal debt provides financial flexibility to fund clinical programs, commercialization or bridge financing without heavy interest burdens. Low leverage reduces bankruptcy risk and preserves strategic options over a multi‑month horizon while the company works to convert revenue growth into profitability.
Bears Say
Persistent Unprofitability And Negative MarginsDeeply negative gross, operating and net margins indicate the business is not yet profitable from operations. Structural unprofitability requires ongoing funding, limits reinvestment capacity and means the company must improve unit economics, pricing or scale to reach sustainable margins over the medium term.
Negative Operating And Free Cash FlowNegative operating and free cash flow reflect a cash burn profile that will necessitate external financing or equity raises. This constrains the company’s ability to scale commercial efforts or fund trials without dilution, increasing execution risk and impacting strategic flexibility over coming months.
Limited Internal Resources (very Small Team)A headcount of six suggests limited commercial, regulatory and manufacturing bandwidth. For a device requiring clinician training and procedure adoption, such a small team can slow market penetration, post‑market support and scaling, increasing reliance on partners and slowing revenue conversion.
OncoSil Medical Ltd News
OSL FAQ
What was OncoSil Medical Ltd’s price range in the past 12 months?
OncoSil Medical Ltd lowest share price was AU$0.37 and its highest was AU$2.08 in the past 12 months.
What is OncoSil Medical Ltd’s market cap?
OncoSil Medical Ltd’s market cap is AU$38.92M.
When is OncoSil Medical Ltd’s upcoming earnings report date?
OncoSil Medical Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 35 days.
How were OncoSil Medical Ltd’s earnings last quarter?
OncoSil Medical Ltd released its earnings results on Feb 23, 2026. The company reported -AU$0.242 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is OncoSil Medical Ltd overvalued?
According to Wall Street analysts OncoSil Medical Ltd’s price is currently Overvalued.
Does OncoSil Medical Ltd pay dividends?
OncoSil Medical Ltd does not currently pay dividends.
What is OncoSil Medical Ltd’s EPS estimate?
OncoSil Medical Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoSil Medical Ltd have?
OncoSil Medical Ltd has 30,889,430 shares outstanding.
What happened to OncoSil Medical Ltd’s price movement after its last earnings report?
OncoSil Medical Ltd reported an EPS of -AU$0.242 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.538%.
Which hedge fund is a major shareholder of OncoSil Medical Ltd?
Currently, no hedge funds are holding shares in AU:OSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OncoSil Medical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
―
20 days / 200 days
Momentum
-67.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-37.99%
Trailing 12-Months
Company Description
OncoSil Medical Ltd
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company’s lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
Technical Analysis
Polynovo
―
Impedimed Limited
―
Cyclopharm Limited
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―